Simple Summary Despite improving rates of pathologic complete response (pCR; the
absence of invasive cancer at the time of surgery) among patients with breast cancer who …

Importance With the increasing delivery of neoadjuvant chemotherapy (NACT) for patients
with breast cancer in the US, it is important to know whether there is differential response to …

Importance Among patients with breast cancer, inconsistent findings have been published
on racial disparities in achieving pathologic complete response (pCR) after neoadjuvant …

BACKGROUND: The current study was conducted to evaluate the influence of race/ethnicity
and tumor subtype in pathologic complete response (pCR) following treatment with …

Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) for
breast cancer among black women and women who are overweight or obese, but this may …

Purpose To explore racial differences in the use and outcome of neoadjuvant chemotherapy
for breast cancer. Methods The National Cancer Data Base was queried to identify women …

Purpose To examine the association between race and clinical outcomes (pathological
complete response [pCR]; recurrence-free survival [RFS], and overall survival [OS]) in …

We evaluated how race, insurance status, and other sociodemographic, tumor, and
treatment variables influenced the response to neoadjuvant chemotherapy (NAC) in breast …

Purpose: Breast cancer in young women is associated with an aggressive tumor biology and
higher risk of recurrence. Pathologic complete response (pCR) after neoadjuvant therapy …

Objective: There is insufficient information on predictors of pathologic complete response
(pCR) to neoadjuvant chemotherapy (NAC) in breast carcinoma that also presented clinical …